1-[3-[3-(5-hydroxypyridin-2-yl)-1,2,4-oxadiazol-5-yl]propanoyl]-4,5,6,7-tetrahydro-2H-indazol-3-one | 1022144-20-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 1-[3-[3-(5-hydroxypyridin-2-yl)-1,2,4-oxadiazol-5-yl]propanoyl]-4,5,6,7-tetrahydro-2H-indazol-3-one
• CAS: 1022144-20-2
• 化学式: C₁₇H₁₇N₅O₄
• 分子量: 355.353
• InChiKey: RLJBCKSVDYDQNJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  26
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  121
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  1-[3-[3-[5-[(4-methoxyphenyl)methoxy]pyridin-2-yl]-1,2,4-oxadiazol-5-yl]propanoyl]-4,5,6,7-tetrahydro-2H-indazol-3-one 在 三异丙基硅烷 、 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 生成 1-[3-[3-(5-hydroxypyridin-2-yl)-1,2,4-oxadiazol-5-yl]propanoyl]-4,5,6,7-tetrahydro-2H-indazol-3-one
  参考文献：
  名称：

  WO2008/51403

  摘要：

  公开号：

文献信息

• Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment
  申请人：Beresis Richard T.

  公开号：US20100204278A1

  公开（公告）日：2010-08-12

  The present invention encompasses compounds of Formula (I) as well as pharmaceutically acceptable salts and hydrates thereof, that are useful for treating atherosclerosis, dyslipidemias and the like. Pharmaceutical compositions and methods of use are also included.

  本发明涵盖了公式（I）的化合物，以及其药学上可接受的盐和水合物，可用于治疗动脉粥样硬化，血脂异常等。还包括制药组合物和使用方法。
• COMBINATION TABLET WITH CHEWABLE OUTER LAYER
  申请人：Vitalis LLC

  公开号：US20170042821A1

  公开（公告）日：2017-02-16

  A pharmaceutical composition in the form of a combination tablet is described. The tablet has a rapidly absorbed component that enters the circulation by traversing the buccal mucosa, oral mucosa and combinations thereof, and a more slowly absorbed component that is swallowed. The therapeutic agent in the swallowed portion is absorbed across the gastric mucosa. The combination tablet may be modified, by varying the specific combinations of excipients, fillers, and the like to effect distinct release rates. In addition, the rapid and slow components may have identical or different therapeutic agents depending on the application to a specific medical condition. One embodiment of the combination tablet includes a prostaglandin inhibitor in the rapidly absorbed component in order to mitigate the side effects of immediate release niacin that is in the slow absorbing component. Such combination compositions will increase patient compliance with various dosing regimens due to the resultant decrease in the number of tablets that a patient would need to take on a daily basis.
• Combination Tablet With Chewable Outer Layer
  申请人：Vitalis LLC

  公开号：US20200046644A1

  公开（公告）日：2020-02-13

  A pharmaceutical composition in the form of a combination tablet is described. The tablet has a rapidly absorbed component that enters the circulation by traversing the buccal mucosa, oral mucosa and combinations thereof, and a more slowly absorbed component that is swallowed. The therapeutic agent in the swallowed portion is absorbed across the gastric mucosa. The combination tablet may be modified, by varying the specific combinations of excipients, fillers, and the like to effect distinct release rates. In addition, the rapid and slow components may have identical or different therapeutic agents depending on the application to a specific medical condition. One embodiment of the combination tablet includes a prostaglandin inhibitor in the rapidly absorbed component in order to mitigate the side effects of immediate release niacin that is in the slow absorbing component. Such combination compositions will increase patient compliance with various dosing regimens due to the resultant decrease in the number of tablets that a patient would need to take on a daily basis.
• [EN] NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT<br/>[FR] AGONISTES DE RÉCEPTEUR DE NIACINE, COMPOSITIONS CONTENANT CES COMPOSES ET PROCÉDÉS DE TRAITEMENT
  申请人：MERCK & CO INC

  公开号：WO2008051403A2

  公开（公告）日：2008-05-02

  [EN] The present invention encompasses compounds of Formula (I) as well as pharmaceutically acceptable salts and hydrates thereof, that are useful for treating atherosclerosis, dyslipidemias and the like. Pharmaceutical compositions and methods of use are also included.
  [FR] L'invention concerne des composes de la formule (I) ainsi que des sels et des hydrates pharmaceutiquement acceptables de ceux-ci, lesquels sont utiles dans le traitement de l'athérosclérose, des dyslipidémies et analogue. L'invention concerne également des compositions pharmaceutiques et des procédés.
• [EN] GPR109A AGONISTS FOR THE TREATMENT OF CEREBRAL ISCHEMIA<br/>[FR] AGONISTES DE GPR109A POUR LE TRAITEMENT DE L'ISCHÉMIE CÉRÉBRALE
  申请人：UNIV RUPRECHT KARLS HEIDELBERG

  公开号：WO2011057110A1

  公开（公告）日：2011-05-12

  The present invention describes agonists for G Protein-coupled receptor 109A (GPR109A), compositions comprising the GPR109A agonists, and methods of using them. GPR109A agonists are used in methods for the treatment, prevention, and alleviation of an ischemic condition, such as cerebral ischemia.